Corcept Therapeutics (NASDAQ:CORT - Get Free Report) announced its earnings results on Monday. The biotechnology company reported $0.17 EPS for the quarter, meeting analysts' consensus estimates of $0.17, Zacks reports. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. Corcept Therapeutics updated its FY 2025 guidance to EPS.
Corcept Therapeutics Stock Up 1.6 %
Corcept Therapeutics stock traded up $1.17 during mid-day trading on Monday, hitting $73.94. The company had a trading volume of 2,212,724 shares, compared to its average volume of 1,120,635. Corcept Therapeutics has a 1 year low of $23.02 and a 1 year high of $117.33. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The stock has a market cap of $7.84 billion, a price-to-earnings ratio of 58.68 and a beta of 0.22. The business has a fifty day moving average of $65.70 and a 200 day moving average of $60.17.
Analyst Ratings Changes
A number of analysts have recently weighed in on CORT shares. StockNews.com downgraded shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, February 28th. HC Wainwright upped their target price on Corcept Therapeutics from $115.00 to $150.00 and gave the stock a "buy" rating in a report on Monday, March 31st. Canaccord Genuity Group boosted their price target on Corcept Therapeutics from $130.00 to $142.00 and gave the stock a "buy" rating in a research report on Tuesday, April 1st. Truist Financial upped their price target on Corcept Therapeutics from $76.00 to $150.00 and gave the stock a "buy" rating in a research report on Monday, March 31st. Finally, Piper Sandler boosted their price objective on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the company an "overweight" rating in a report on Thursday, April 3rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Corcept Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $143.25.
Read Our Latest Analysis on CORT
Insider Activity
In related news, insider Joseph Douglas Lyon sold 421 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $60.58, for a total transaction of $25,504.18. Following the sale, the insider now owns 9,009 shares of the company's stock, valued at $545,765.22. This trade represents a 4.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sean Maduck sold 100,000 shares of the stock in a transaction on Monday, March 31st. The stock was sold at an average price of $100.54, for a total value of $10,054,000.00. Following the transaction, the insider now directly owns 85,622 shares in the company, valued at approximately $8,608,435.88. This represents a 53.87 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 163,124 shares of company stock valued at $15,117,614. 20.50% of the stock is currently owned by company insiders.
Corcept Therapeutics Company Profile
(
Get Free Report)
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Corcept Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corcept Therapeutics wasn't on the list.
While Corcept Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
